Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) saw a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 7,940,000 shares, an increase of 18.0% from the June 15th total of 6,730,000 shares. Approximately 21.4% of the shares of the company are short sold. Based on an average daily trading volume, of 456,700 shares, the days-to-cover ratio is currently 17.4 days.
Apogee Therapeutics Stock Up 1.4 %
APGE opened at $50.08 on Wednesday. The company has a market cap of $2.93 billion and a PE ratio of -9.54. Apogee Therapeutics has a twelve month low of $14.19 and a twelve month high of $72.29. The company has a 50-day moving average price of $44.37 and a 200 day moving average price of $45.58.
Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last released its earnings results on Monday, May 13th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.04). As a group, sell-side analysts expect that Apogee Therapeutics will post -2.64 earnings per share for the current year.
Wall Street Analyst Weigh In
Get Our Latest Stock Analysis on APGE
Insider Buying and Selling
In other news, insider Carl Dambkowski sold 5,995 shares of the company’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $37.60, for a total value of $225,412.00. Following the sale, the insider now directly owns 294,793 shares of the company’s stock, valued at approximately $11,084,216.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $37.26, for a total transaction of $558,900.00. Following the completion of the transaction, the chief executive officer now directly owns 1,474,487 shares in the company, valued at $54,939,385.62. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Carl Dambkowski sold 5,995 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total value of $225,412.00. Following the completion of the sale, the insider now owns 294,793 shares in the company, valued at approximately $11,084,216.80. The disclosure for this sale can be found here. 36.10% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Apogee Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in APGE. Vanguard Group Inc. lifted its stake in shares of Apogee Therapeutics by 60.7% in the first quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock worth $124,173,000 after buying an additional 705,795 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Apogee Therapeutics by 0.3% during the 4th quarter. Wellington Management Group LLP now owns 1,591,478 shares of the company’s stock worth $44,358,000 after buying an additional 4,749 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Apogee Therapeutics by 51.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,170,327 shares of the company’s stock worth $77,770,000 after acquiring an additional 399,646 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Apogee Therapeutics by 9.3% during the 4th quarter. Franklin Resources Inc. now owns 1,089,780 shares of the company’s stock worth $30,448,000 after purchasing an additional 92,423 shares during the last quarter. Finally, Darwin Global Management Ltd. purchased a new stake in shares of Apogee Therapeutics in the 1st quarter valued at approximately $55,300,000. Institutional investors and hedge funds own 79.04% of the company’s stock.
Apogee Therapeutics Company Profile
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Read More
- Five stocks we like better than Apogee Therapeutics
- How Can Investors Benefit From After-Hours Trading
- Tech Leader’s Stock Split: Is It the Right Time to Buy?
- Industrial Products Stocks Investing
- Could the Economy be Bottoming? Major Bank’s Earnings Say Yes
- The How And Why of Investing in Oil Stocks
- Seize This Prime Stock Opportunity on Amazon Prime Days
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.